Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. Pharma giants Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,
4d
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
The team categorized pediatric obesity treatment response, based on changes in body mass index standard deviation score, as ...
A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss ...
When children with obesity undergo weight-loss treatment, the effects have repercussions later in life and the risk of serious health problems and premature death is lower as they reach young ...
Compared with poor response, good response to obesity treatment was associated with lower risk of type 2 diabetes (adjusted ...
The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...
Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback